Cargando…
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002311/ https://www.ncbi.nlm.nih.gov/pubmed/29551008 http://dx.doi.org/10.1007/s13555-018-0234-5 |
| _version_ | 1783332173556744192 |
|---|---|
| author | Spindeldreher, Sebastian Maillère, Bernard Correia, Evelyne Tenon, Maxime Karle, Anette Jarvis, Philip Kolbinger, Frank |
| author_facet | Spindeldreher, Sebastian Maillère, Bernard Correia, Evelyne Tenon, Maxime Karle, Anette Jarvis, Philip Kolbinger, Frank |
| author_sort | Spindeldreher, Sebastian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6002311 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60023112018-06-29 Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab Spindeldreher, Sebastian Maillère, Bernard Correia, Evelyne Tenon, Maxime Karle, Anette Jarvis, Philip Kolbinger, Frank Dermatol Ther (Heidelb) Author Correction Springer Healthcare 2018-03-17 /pmc/articles/PMC6002311/ /pubmed/29551008 http://dx.doi.org/10.1007/s13555-018-0234-5 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Author Correction Spindeldreher, Sebastian Maillère, Bernard Correia, Evelyne Tenon, Maxime Karle, Anette Jarvis, Philip Kolbinger, Frank Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| title | Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| title_full | Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| title_fullStr | Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| title_full_unstemmed | Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| title_short | Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab |
| title_sort | author correction: secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002311/ https://www.ncbi.nlm.nih.gov/pubmed/29551008 http://dx.doi.org/10.1007/s13555-018-0234-5 |
| work_keys_str_mv | AT spindeldrehersebastian authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab AT maillerebernard authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab AT correiaevelyne authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab AT tenonmaxime authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab AT karleanette authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab AT jarvisphilip authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab AT kolbingerfrank authorcorrectionsecukinumabdemonstratessignificantlylowerimmunogenicitypotentialcomparedtoixekizumab |